| 词条 | Phencyclidine | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 释义 |
| Verifiedfields = changed | Watchedfields = changed | verifiedrevid = 464373911 | drug_name = | type = | IUPAC_name = 1-(1-Phenylcyclohexyl)piperidine | image = Phencyclidine structure.svg | width = 135px | alt = | caption = | image2 = Phencyclidine-from-xtal-3D-balls.png | width2 = 225px | tradename = Sernyl, Sernylan (both discontinued) | Drugs.com = {{drugs.com|parent|phencyclidine}} | MedlinePlus = | licence_EU = | licence_US = | pregnancy_AU = | pregnancy_US = | pregnancy_category = | legal_AU = S9 | legal_CA = Schedule I | legal_UK = Class A | legal_US = Schedule II | legal_DE = Anlage I | routes_of_administration = Smoking, injection, snorted, by mouth[1] | legal_status = | addiction_liability = Variable reported from low to high[2][1][2] | onset = 2–60 min[3] | metabolism = Oxidative hydration in liver by cytochrome P450 enzymes | metabolites = PCHP, PPC and PCAA | elimination_half-life = 7–46 hours | duration_of_action = 6–48 hours[3] |excretion = Kidney | IUPHAR_ligand = 4282 | CAS_number_Ref = {{cascite|correct|??}} | CAS_number = 77-10-1 | ATC_prefix = None | PubChem = 6468 | DrugBank_Ref = {{drugbankcite|correct|drugbank}} | DrugBank = DB03575 | ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}} | ChemSpiderID = 6224 | UNII_Ref = {{fdacite|correct|FDA}} | UNII = J1DOI7UV76 | KEGG_Ref = {{keggcite|correct|kegg}} | KEGG = C07575 | ChEBI_Ref = {{ebicite|changed|EBI}} | ChEBI = 8058 | ChEMBL_Ref = {{ebicite|correct|EBI}} | ChEMBL = 275528 | synonyms = Phenylcyclohexyl piperidine, angel dust, sherm, wet, animal tranquilizer, embalming fluid, wack[7] | C = 17| H = 25| N = 1 | melting_point = 46.5 | boiling_point = 136 | SMILES = C1(C2(N3CCCCC3)CCCCC2)=CC=CC=C1 | StdInChI_Ref = {{stdinchicite|correct|chemspider}} | StdInChI = 1S/C17H25N/c1-4-10-16(11-5-1)17(12-6-2-7-13-17)18-14-8-3-9-15-18/h1,4-5,10-11H,2-3,6-9,12-15H2 | StdInChIKey_Ref = {{stdinchicite|correct|chemspider}} | StdInChIKey = JTJMJGYZQZDUJJ-UHFFFAOYSA-N }}Phencyclidine (PCP), also known as angel dust among other names, is a drug used for its mind-altering effects.[4] PCP may cause hallucinations, distorted perceptions of sounds, and violent behavior.[5][10] As a recreational drug, it is typically smoked, but may be taken by mouth, snorted, or injected.[5][6] It may also be mixed with cannabis or tobacco.[4]Adverse effects may include seizures, coma, addiction, and an increased risk of suicide.[5] Flashbacks may occur despite stopping usage.[7] Chemically, PCP is a member of the arylcyclohexylamine class, and pharmacologically, it is a dissociative anesthetic.[16][8] PCP works primarily as an NMDA receptor antagonist.[9] PCP is most commonly used in the United States.[10] While usage peaked there in the 1970s,[11] between 2005 and 2011 an increase in visits to emergency departments as a result of the drug occurred.[5] As of 2017 in the United States about 1% of people in grade twelve reported using PCP in the prior year while 2.9% of those over the age of 25 reported using it at some point in their life.[12] PCP was initially made in 1926 and brought to market as an anesthetic medication in the 1950s.[8][13] Its use in humans was disallowed in the United States in 1965 due to the high rates of side effects while its use in other animals was disallowed in 1978.[4][14][8] Moreover, ketamine was discovered and was better tolerated as an anesthetic.[14] PCP is classified as a schedule II drug in the United States.[4] A number of derivatives of PCP have been sold for recreational and non-medical use.[15] {{TOC limit|3}}Recreational usesPhencyclidine is used for its ability to induce a dissociative state. [16] Effects{{See also|Excited delirium}}Behavioral effects can vary by dosage. Low doses produce a numbness in the extremities and intoxication, characterized by staggering, unsteady gait, slurred speech, bloodshot eyes, and loss of balance. Moderate doses (5–10 mg intranasal, or 0.01–0.02 mg/kg intramuscular or intravenous) will produce analgesia and anesthesia. High doses may lead to convulsions.[17] The drug is often illegally produced under poorly-controlled conditions; this means that users may be unaware of the actual dose they are taking.[18] Psychological effects include severe changes in body image, loss of ego boundaries, paranoia, and depersonalization. Psychosis, agitation and dysphoria, hallucinations, blurred vision, euphoria, and suicidal impulses are also reported, as well as occasional aggressive behavior.[19][35]{{rp|48–49}}[17] Like many other drugs, PCP has been known to alter mood states in an unpredictable fashion, causing some individuals to become detached, and others to become animated. PCP may induce feelings of strength, power, and invulnerability as well as a numbing effect on the mind.[6] Studies by the Drug Abuse Warning Network in the 1970s show that media reports of PCP-induced violence are greatly exaggerated and that incidents of violence are unusual and often limited to individuals with reputations for aggression regardless of drug use.[35]{{rp|48}} Although uncommon, events of PCP-intoxicated individuals acting in an unpredictable fashion, possibly driven by their delusions or hallucinations, have been publicized.{{citation needed|date=February 2016}} One example is the case of Big Lurch, a former rapper with a history of violent crime, who was convicted of murdering and cannibalizing his roommate while under the influence of PCP.[20] Other commonly cited types of incidents include inflicting property damage and self-mutilation of various types, such as pulling one's own teeth.[35]{{rp|48}}[20] These effects were not noted in its medicinal use in the 1950s and 1960s however, and reports of physical violence on PCP have often been shown to be unfounded.[21][22] Recreational doses of the drug also occasionally appear to induce a psychotic state that resembles a schizophrenic episode.[23] Users generally report feeling detached from reality.[24] Symptoms are summarized by the mnemonic device RED DANES: rage, erythema (redness of skin), dilated pupils, delusions, amnesia, nystagmus (oscillation of the eyeball when moving laterally), excitation, and skin dryness.[25] AddictionPCP is self-administered and induces ΔFosB expression in the D1-type medium spiny neurons of the nucleus accumbens,[26][27] and accordingly, excessive PCP use is known to cause addiction.[26] PCP's rewarding and reinforcing effects are at least partly mediated by blocking the NMDA receptors in the glutamatergic inputs to D1-type medium spiny neurons in the nucleus accumbens.[26] PCP has been shown to produce conditioned place aversion and conditioned place preference in animal studies.[28] Methods of administrationPCP comes in both powder and liquid forms (PCP base is dissolved most often in ether), but typically it is sprayed onto leafy material such as cannabis, mint, oregano, tobacco, parsley, or ginger leaves, then smoked.{{citation needed|date=July 2012}}
Management of intoxicationManagement of PCP intoxication mostly consists of supportive care – controlling breathing, circulation, and body temperature – and, in the early stages, treating psychiatric symptoms.[30][31][32] Benzodiazepines, such as lorazepam, are the drugs of choice to control agitation and seizures (when present). Typical antipsychotics such as phenothiazines and haloperidol have been used to control psychotic symptoms, but may produce many undesirable side effects – such as dystonia – and their use is therefore no longer preferred; phenothiazines are particularly risky, as they may lower the seizure threshold, worsen hyperthermia, and boost the anticholinergic effects of PCP.[30][31] If an antipsychotic is given, intramuscular haloperidol has been recommended.[32][33][34] Forced acid diuresis (with ammonium chloride or, more safely, ascorbic acid) may increase clearance of PCP from the body, and was somewhat controversially recommended in the past as a decontamination measure.[30][31][32] However, it is now known that only around 10% of a dose of PCP is removed by the kidneys, which would make increased urinary clearance of little consequence; furthermore, urinary acidification is dangerous, as it may induce acidosis and worsen rhabdomyolysis (muscle breakdown), which is not an unusual manifestation of PCP toxicity.[30][31]PharmacologyPharmacodynamics
PCP is well known for its primary action on the NMDA receptor, an ionotropic glutamate receptor, in rats and in rat brain homogenate.[45][41] As such, PCP is an NMDA receptor antagonist. The role of NMDAR antagonism in the effect of PCP, ketamine, and related dissociative agents was first published in the early 1980s by David Lodge[46] and colleagues.[15] Other NMDA receptor antagonists include ketamine,[47] tiletamine,[48] dextromethorphan,[49] nitrous oxide, and dizocilpine (MK-801). Research also indicates that PCP inhibits nicotinic acetylcholine receptors (nAChRs) among other mechanisms. Analogues of PCP exhibit varying potency at nACh receptors[50] and NMDA receptors.[51] Findings demonstrate that presynaptic nAChRs and NMDA receptor interactions influence postsynaptic maturation of glutamatergic synapses and consequently impact synaptic development and plasticity in the brain.[52] These effects can lead to inhibition of excitatory glutamate activity in certain brain regions such as the hippocampus[53] and cerebellum[54] thus potentially leading to memory loss as one of the effects of prolonged use. Acute effects on the cerebellum manifest as changes in blood pressure, breathing rate, pulse rate, and loss of muscular coordination during intoxication.[7] PCP, like ketamine, also acts as a potent dopamine D2High receptor partial agonist in rat brain homogenate[41] and has affinity for the human cloned D2High receptor.[55] This activity may be associated with some of the other more psychotic features of PCP intoxication, which is evidenced by the successful use of D2 receptor antagonists (such as haloperidol) in the treatment of PCP psychosis.[56] In addition to its well explored interactions with NMDA receptors, PCP has also been shown to inhibit dopamine reuptake, and thereby leads to increased extracellular levels of dopamine and hence increased dopaminergic neurotransmission.[57] However, PCP has little affinity for the human monoamine transporters, including the dopamine transporter (DAT).[37] Instead, its inhibition of monoamine reuptake may be mediated by interactions with allosteric sites on the monoamine transporters.[37] PCP is notably a high-affinity ligand of the PCP site 2 (Ki = 154 nM), a not-well-characterized site associated with monoamine reuptake inhibition.[43] Studies on rats indicate that PCP interacts indirectly with opioid receptors (endorphin and enkephalin) to produce analgesia.[58] A binding study assessed PCP at 56 sites including neurotransmitter receptors and transporters and found that PCP had Ki values of >10,000 nM at all sites except the dizocilpine (MK-801) site of the NMDA receptor (Ki = 59 nM), the σ2 receptor (PC12) (Ki = 136 nM), and the serotonin transporter (Ki = 2,234 nM).[37] The study notably found Ki values of >10,000 nM for the D2 receptor, the opioid receptors, the σ1 receptor, and the dopamine and norepinephrine transporters.[37] These results suggest that PCP is a highly selective ligand of the NMDAR and σ2 receptor.[37] However, PCP may also interact with allosteric sites on the monoamine transporters to produce inhibition of monoamine reuptake.[37] Mechanism of actionPhencyclidine is an NMDA receptor antagonist that blocks the activity of the NMDA receptor to cause anaesthesia and analgesia without causing cardiorespiratory depression.[59][60] NMDA is an excitatory receptor in the brain, when activated normally the receptor acts as an ion channel and there is an influx of positive ions through the channel to cause nerve cell depolarisation. Phencyclidine enters the ion channel and binds, reversibly and non-competitively, inside the channel pore to block the entry of positive ions to the cell therefore inhibiting cell depolarisation.[59][61] NeurotoxicitySome studies found that, like other NMDA receptor antagonists, PCP can cause a kind of brain damage called Olney's lesions in rats.[62][63] Studies conducted on rats showed that high doses of the NMDA receptor antagonist dizocilpine caused reversible vacuoles to form in certain regions of the rats' brains. All studies of Olney's lesions have only been performed on non-human animals and may not apply to humans. One unpublished study by Frank Sharp reportedly showed no damage by the NDMA antagonist, ketamine, a similar drug, far beyond recreational doses,[64] but due to the study never having been published, its validity is controversial. PCP has also been shown to cause schizophrenia-like changes in N-acetylaspartate and N-acetylaspartylglutamate levels in the rat brain, which are detectable both in living rats and upon necropsy examination of brain tissue.[65] It also induces symptoms in humans that mimic schizophrenia.[66] PCP not only produced symptoms similar to schizophrenia, it also yielded electroencephalogram changes in the thalamocortical pathway (increased delta decreased alpha) and in the hippocampus (increase theta bursts) that were similar to those in schizophrenia.[67] PCP induced augmentation of dopamine release may link the NMDA and DA hypothesis of schizophrenia.[68] PharmacokineticsPCP is metabolized into PCHP, PPC and PCAA. 90% of phencycledine is metabolised by oxidative hydroxylation in the liver on first pass. Metabolites are glucroniated and excreted in the urine. 9% of the drug is excreted in its unchanged form.[60] When smoked, some of the compound is broken down by heat into 1-phenylcyclohexene (PC) and piperidine. It takes 15 to 60 minutes for effects of phencyclidine to come into action.[60] ChemistryPCP is an arylcyclohexylamine. AnaloguesFewer than 30 different analogues of PCP were reported as being used on the street during the 1970s and 1980s, mainly in the United States.[15] The best known of these are rolicyclidine (PCPy or 1-(1-phenylcyclohexyl)pyrrolidine); eticyclidine (PCE or N-ethyl-1-phenylcyclohexylamine); and tenocyclidine (TCP or 1-(1-(2-thienyl)cyclohexyl)piperidine).[69] Only of a few of these compounds were widely used.[15] The generalized structural motif required for PCP-like activity is derived from structure-activity relationship studies of PCP derivatives, and summarized in the illustration (right). All of these derivatives are likely to share some of their psychoactive effects with PCP itself, although a range of potencies and varying mixtures of anesthetic, dissociative and stimulant effects are known, depending on the particular drug and its substituents. In some countries such as the United States, Australia, and New Zealand, all of these compounds would be considered controlled substance analogues of PCP, and are hence illegal drugs if sold for human consumption, even though many of them have never been made or tested.[70][71]{{Clarify|date=November 2008}} Other analogues of PCP include 3-HO-PCP, 3-MeO-PCMo, and 3-MeO-PCP. UsagePCP began to emerge as a recreational drug in major cities in the United States in 1960s.[5] In 1978, People magazine and Mike Wallace of 60 Minutes called PCP the country's "number one" drug problem. Although recreational use of the drug had always been relatively low, it began declining significantly in the 1980s. In surveys, the number of high school students admitting to trying PCP at least once fell from 13% in 1979 to less than 3% in 1990.[72]{{rp|46–49}} HistoryIt is commonly mistakenly reported that PCP was first synthesized in 1926.[73] This early synthesis, in fact, refers to the PCP intermediate PCC.[15] PCP was actually discovered by Victor Maddox, a chemist at Parke-Davis in Michigan, while investigating synthetic analgesic agents. Although unexpected, PCP was identified as potentially interesting, and as such, was submitted for pharmacological testing. The promising results of these pharmacological investigations led to the rapid development of PCP. It was approved for use as an investigational drug under the brand names Sernyl and Sernylan in the 1950s as an anesthetic, but because of its long terminal half-life and adverse side effects, such as hallucinations, mania, delirium, and disorientation, it was removed from the market in 1965 and limited to veterinary use.[15][74][75] RegulationPCP is a Schedule II substance in the United States and its ACSCN is 7471.[76] Its manufacturing quota for 2014 was 19 grams.[77] It is a Schedule I drug by the Controlled Drugs and Substances act in Canada, a List I drug of the Opium Law in the Netherlands, and a Class A substance in the United Kingdom.[78] References1. ^{{cite book|last1=Stobo|first1=John D.|last2=Traill|first2=Thomas A.|last3=Hellmann|first3=David B.|last4=Ladenson|first4=Paul W.|last5=Petty|first5=Brent G.|title=The Principles and Practice of Medicine|date=1996|publisher=McGraw Hill Professional|isbn=9780071383653|page=933|url=https://books.google.co.jp/books?id=aA9mMB3lDh4C&q|language=en|quote= high abuse liability}} 2. ^{{cite book|last1=Fetting|first1=Margaret|title=Perspectives on Substance Use, Disorders, and Addiction: With Clinical Cases|date=2015|publisher=SAGE Publications|isbn=9781483377773|page=145|url=https://books.google.co.jp/books?id=7qxiCgAAQBAJ&pg=PT145|language=en}} 3. ^1 {{cite book|last1=Riviello|first1=Ralph J.|title=Manual of forensic emergency medicine : a guide for clinicians|date=2010|publisher=Jones and Bartlett Publishers|location=Sudbury, Mass.|isbn=9780763744625|pages=41–42|url=https://books.google.com/books?id=keng9ELAE2IC&pg=PA41}} 4. ^1 2 3 4 {{cite web|title=PCP Fast Facts|url=http://www.justice.gov/archive/ndic/pubs4/4440/|publisher=National Drug Intelligence Center|accessdate=19 February 2018|date=2003}} 5. ^1 2 3 4 {{cite journal|last1=Bush|first1=DM|title=Emergency Department Visits Involving Phencyclidine (PCP)|date=2013|pmid=27656747}} 6. ^1 2 {{cite web|url=http://drugabuse.gov/infofacts/hallucinogens.html|title=NIDA InfoFacts: Hallucinogens – LSD, Peyote, Psilocybin, and PCP|publisher=National Institute on Drug Abuse|accessdate=2018-02-19}} 7. ^1 2 {{cite web|title=Hallucinogens|url=https://www.drugabuse.gov/publications/drugfacts/hallucinogens|publisher=National Institute on Drug Abuse|accessdate=20 February 2018|language=en|date=January 2016}} 8. ^1 2 {{cite book|last1=Zedeck|first1=Beth E.|last2=Zedeck|first2=Morris S.|title=Forensic Pharmacology|date=2007|publisher=Infobase Publishing|isbn=9781438103822|page=97|url=https://books.google.com/books?id=tyBE3F5ACK4C&pg=PA97|language=en}} 9. ^1 {{cite book|last1=Marion|first1=Nancy E.|last2=Oliver|first2=Willard M.|title=Drugs in American Society: An Encyclopedia of History, Politics, Culture, and the Law [3 volumes]|date=2014|publisher=ABC-CLIO|isbn=9781610695961|page=732|url=https://books.google.co.jp/books?id=c5PgBQAAQBAJ&pg=PA732|language=en}} 10. ^{{cite web|title=GINAD|url=http://www.ginad.org/en/drugs/drugs/306/pcp-|website=www.ginad.org|language=en}} 11. ^{{cite web|title=PCP|url=http://www.cesar.umd.edu/cesar/drugs/pcp.asp|website=CESAR|accessdate=20 February 2018|language=en}} 12. ^{{cite web|title=Hallucinogens|url=https://www.drugabuse.gov/drugs-abuse/hallucinogens|website=NIAD|accessdate=20 February 2018}} 13. ^{{cite book|last1=Bunney|first1=W. E. Jr|last2=Hippius|first2=Hanns|last3=Laakmann|first3=Gregor|last4=Schmauß|first4=Max|title=Neuropsychopharmacology: Proceedings of the XVIth C.I.N.P. Congress, Munich, August, 15-19, 1988|date=2012|publisher=Springer Science & Business Media|isbn=9783642740343|page=717|url=https://books.google.com/books?id=tX7nCAAAQBAJ&pg=PA717|language=en}} 14. ^1 {{cite book|last1=Tasman|first1=Allan|last2=Kay|first2=Jerald|last3=Lieberman|first3=Jeffrey A.|last4=First|first4=Michael B.|last5=Riba|first5=Michelle|title=Psychiatry, 2 Volume Set|date=2015|publisher=John Wiley & Sons|isbn=9781118753361|page=4943|url=https://books.google.com/books?id=l2KRBgAAQBAJ&pg=PT4843|language=en}} 15. ^1 2 3 4 5 {{cite journal | vauthors = Morris H, Wallach J | title = From PCP to MXE: a comprehensive review of the non-medical use of dissociative drugs | journal = Drug Testing and Analysis | volume = 6 | issue = 7–8 | pages = 614–32 | year = 2014 | pmid = 24678061 | doi = 10.1002/dta.1620 }} 16. ^{{cite journal |last1=Millan |first1=M. J. |last2=Brocco |first2=M. |last3=Gobert |first3=A. |last4=Joly |first4=F. |last5=Bervoets |first5=K. |last6=Rivet |first6=J. -M. |last7=Newman-Tancredi |first7=A. |last8=Audinot |first8=V. |last9=Maurel |first9=S. |title=Contrasting mechanisms of action and sensitivity to antipsychotics of phencyclidine versus amphetamine: importance of nucleus accumbens 5-HT sites for PCP-induced locomotion in the rat |journal=European Journal of Neuroscience |date=December 1999 |volume=11 |issue=12 |pages=4419–4432 |doi=10.1046/j.1460-9568.1999.00858.x }} 17. ^1 Diaz, Jaime. How Drugs Influence Behavior. Englewood Cliffs: Prentice Hall, 1996. 18. ^{{cite web|url=http://faculty.washington.edu/chudler/pcp.html|title=Neuroscience for Kids – PCP|last=Chudler|first=Eric H.|accessdate=2011-01-26|work=Neuroscience for Kids}} 19. ^{{cite journal |last1=Bey |first1=T |last2=Patel |first2=A |title=Phencyclidine intoxication and adverse effects: a clinical and pharmacological review of an illicit drug. |journal=The California Journal of Emergency Medicine |date=February 2007 |volume=8 |issue=1 |pages=9–14 |pmid=20440387 |pmc=2859735 }} 20. ^1 Does PCP turn people into cannibals? The Straight Dope, 2005 21. ^{{cite journal|vauthors=Brecher M, Wang BW, Wong H, Morgan JP|title=Phencyclidine and violence: clinical and legal issues|journal=Journal of Clinical Psychopharmacology|volume=8|issue=6|pages=397–401|date=Dec 1988|pmid=3069880|doi=10.1097/00004714-198812000-00003}} 22. ^{{cite journal|vauthors=Wish ED|title=PCP and crime: just another illicit drug?|journal=NIDA Research Monograph|volume=64|pages=174–89|year=1986|pmid=3086733}} 23. ^{{cite journal|last=Luisada|first=PV|title=The phencyclidine psychosis: phenomenology and treatment|editor-last1=Petersen|editor-first1=RC|editor-last2=Stillman|editor-first2=RC|url=https://archives.drugabuse.gov/sites/default/files/monograph21.pdf|journal=Phencyclidine (PCP) Abuse: An Appraisal|publisher=National Institute on Drug Abuse|location=Rockville, Maryland| year=1978}} 24. ^{{cite journal|vauthors=Pender JW|title=Dissociative anesthesia|journal=California Medicine|volume=117|issue=4|pages=46–7|date=Oct 1972|pmid=18730832|pmc=1518731}} 25. ^{{cite book|first=A. James|last=Giannini|title=Drugs of Abuse|edition=Second|publisher=Los Angeles: Practice Management Information Corp|year=1997|page=126|isbn=978-1-57066-053-5}} 26. ^1 2 3 {{cite book |vauthors=Malenka RC, Nestler EJ, Hyman SE |veditors=Sydor A, Brown RY | title = Molecular Neuropharmacology: A Foundation for Clinical Neuroscience | year = 2009 | publisher = McGraw-Hill Medical | location = New York | isbn = 9780071481274 | pages = 374–375 | edition = 2nd | chapter = Chapter 15: Reinforcement and Addictive Disorders}} 27. ^{{cite journal|last=Nestler|first=EJ|title=Review. Transcriptional mechanisms of addiction: role of DeltaFosB|journal=Philos. Trans. R. Soc. Lond. B Biol. Sci.|volume=363|issue=1507|pages=3245–3255|date=October 12, 2008|pmid=18640924|doi=10.1098/rstb.2008.0067|pmc=2607320|quote=}}{{cite journal|title=Table 1: Drugs of abuse known to induce ΔFosB in nucleus accumbens after chronic administration|pmc=2607320|pmid=18640924|doi=10.1098/rstb.2008.0067|volume=363|issue=1507|date=October 2008|journal=Philos. Trans. R. Soc. Lond. B Biol. Sci.|pages=3245–55|vauthors=Nestler EJ}} 28. ^{{cite journal|last1=Noda|first1=Y.|last2=Nabeshima|first2=T.|title=Neuronal mechanisms of phencyclidine-induced place aversion and preference in the conditioned place preference task|journal=Methods and Findings in Experimental and Clinical Pharmacology|date=1 September 1998|volume=20|issue=7|pages=607–611|pmid=9819806|issn=0379-0355|doi=10.1358/mf.1998.20.7.485726}} 29. ^{{cite web|url=https://www.justice.gov/archive/ndic/pubs11/12208/|title=Fry Fast Facts|publisher=National Drug Intelligence Center}} 30. ^1 2 3 {{cite journal |url=http://www.emedicine.com/med/TOPIC1813.HTM |title=Phencyclidine Toxicity |vauthors=Helman RS, Habal R |date=October 6, 2008 |journal=eMedicine}} Retrieved on November 3, 2008. 31. ^1 2 3 {{cite book |author=Olmedo R |chapter=Chapter 69: Phencyclidine and ketamine |title=Goldfrank's Toxicologic Emergencies |veditors=Goldfrank LR, Flomenbaum NE, Lewin NA, Howland MA, Hoffman RS, Nelson LS |publisher=McGraw-Hill |location=New York |year=2002 |pages=1034–1041 |isbn=978-0-07-136001-2 |chapter-url=https://books.google.com/books?id=HVYyRsuUEc0C&pg=PA1041}} 32. ^1 2 {{cite journal | vauthors = Milhorn HT | title = Diagnosis and management of phencyclidine intoxication | journal = American Family Physician | volume = 43 | issue = 4 | pages = 1293–302 | date = Apr 1991 | pmid = 2008817 }} 33. ^{{cite journal | vauthors = Giannini AJ, Price WA | year = 1985 | title = PCP: Management of acute intoxication | journal = Medical Times | volume = 113 | issue = 9| pages = 43–49 }} 34. ^{{cite journal | vauthors = Giannini AJ, Eighan MS, Loiselle RH, Giannini MC | title = Comparison of haloperidol and chlorpromazine in the treatment of phencyclidine psychosis | journal = Journal of Clinical Pharmacology | volume = 24 | issue = 4 | pages = 202–4 | date = Apr 1984 | pmid = 6725621 | doi = 10.1002/j.1552-4604.1984.tb01831.x }} 35. ^{{cite web | title = PDSP Ki Database | work = Psychoactive Drug Screening Program (PDSP) | author1 = Roth, BL | author2 = Driscol, J | publisher = University of North Carolina at Chapel Hill and the United States National Institute of Mental Health | accessdate = 14 August 2017 | url = https://kidbdev.med.unc.edu/databases/pdsp.php?knowID=0&kiKey=&receptorDD=&receptor=&speciesDD=&species=&sourcesDD=&source=&hotLigandDD=&hotLigand=&testLigandDD=&testFreeRadio=testFreeRadio&testLigand=phencyclidine&referenceDD=&reference=&KiGreater=&KiLess=&kiAllRadio=all&doQuery=Submit+Query}} 36. ^{{cite journal | vauthors = Berton JL, Seto M, Lindsley CW | title = DARK Classics in Chemical Neuroscience: Phencyclidine (PCP) | journal = ACS Chem Neurosci | volume = 9| issue = 10| pages = 2459–2474| date = June 2018 | pmid = 29953199 | doi = 10.1021/acschemneuro.8b00266 | url = }} 37. ^1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 {{cite journal | vauthors = Roth BL, Gibbons S, Arunotayanun W, Huang XP, Setola V, Treble R, Iversen L | title = The ketamine analogue methoxetamine and 3- and 4-methoxy analogues of phencyclidine are high affinity and selective ligands for the glutamate NMDA receptor | journal = PLOS One | volume = 8 | issue = 3 | pages = e59334 | year = 2013 | pmid = 23527166 | pmc = 3602154 | doi = 10.1371/journal.pone.0059334 | url = | bibcode = 2013PLoSO...859334R }} 38. ^{{cite journal | vauthors = Frohlich J, Van Horn JD | title = Reviewing the ketamine model for schizophrenia | journal = J. Psychopharmacol. (Oxford) | volume = 28 | issue = 4 | pages = 287–302 | year = 2014 | pmid = 24257811 | pmc = 4133098 | doi = 10.1177/0269881113512909 | url = }} 39. ^{{cite journal | vauthors = Seeman P, Guan HC | title = Phencyclidine and glutamate agonist LY379268 stimulate dopamine D2High receptors: D2 basis for schizophrenia | journal = Synapse | volume = 62 | issue = 11 | pages = 819–28 | year = 2008 | pmid = 18720422 | doi = 10.1002/syn.20561 | url = }} 40. ^1 {{cite journal | vauthors = Kapur S, Seeman P | title = NMDA receptor antagonists ketamine and PCP have direct effects on the dopamine D(2) and serotonin 5-HT(2)receptors-implications for models of schizophrenia | journal = Mol. Psychiatry | volume = 7 | issue = 8 | pages = 837–44 | year = 2002 | pmid = 12232776 | doi = 10.1038/sj.mp.4001093 | url = }} 41. ^1 2 {{cite journal | vauthors = Seeman P, Guan HC, Hirbec H | title = Dopamine D2High receptors stimulated by phencyclidines, lysergic acid diethylamide, salvinorin A, and modafinil | journal = Synapse | volume = 63 | issue = 8 | pages = 698–704 | year = 2009 | pmid = 19391150 | doi = 10.1002/syn.20647 | url = }} 42. ^{{cite journal | vauthors = Rabin RA, Doat M, Winter JC | title = Role of serotonergic 5-HT2A receptors in the psychotomimetic actions of phencyclidine | journal = Int. J. Neuropsychopharmacol. | volume = 3 | issue = 4 | pages = 333–338 | year = 2000 | pmid = 11343613 | doi = 10.1017/S1461145700002091 | url = }} 43. ^1 2 {{cite journal | vauthors = Rothman RB | title = PCP site 2: a high affinity MK-801-insensitive phencyclidine binding site | journal = Neurotoxicol Teratol | volume = 16 | issue = 4 | pages = 343–53 | year = 1994 | pmid = 7968938 | doi = 10.1016/0892-0362(94)90022-1| url = }} 44. ^1 2 3 {{cite journal | vauthors = Goodman CB, Thomas DN, Pert A, Emilien B, Cadet JL, Carroll FI, Blough BE, Mascarella SW, Rogawski MA, Subramaniam S | title = RTI-4793-14, a new ligand with high affinity and selectivity for the (+)-MK801-insensitive [3H]1-]1-(2-thienyl)cyclohexyl]piperidine binding site (PCP site 2) of guinea pig brain | journal = Synapse | volume = 16 | issue = 1 | pages = 59–65 | year = 1994 | pmid = 8134901 | doi = 10.1002/syn.890160107 | url = }} 45. ^{{cite journal | vauthors = Large CH, Bison S, Sartori I, Read KD, Gozzi A, Quarta D, Antolini M, Hollands E, Gill CH, Gunthorpe MJ, Idris N, Neill JC, Alvaro GS | title = The efficacy of sodium channel blockers to prevent phencyclidine-induced cognitive dysfunction in the rat: potential for novel treatments for schizophrenia | journal = The Journal of Pharmacology and Experimental Therapeutics | volume = 338 | issue = 1 | pages = 100–13 | date = Jul 2011 | pmid = 21487071 | doi = 10.1124/jpet.110.178475 }} 46. ^{{Cite journal | author = N. A. Anis, S. C. Berry, N. R. Burton & D. Lodge | title = The dissociative anaesthetics, ketamine and phencyclidine, selectively reduce excitation of central mammalian neurones by N-methyl-aspartate | journal = British Journal of Pharmacology | volume = 79 | issue = 2 | pages = 565–575 | year = 1983 | pmc = 2044888 | pmid = 6317114 | doi=10.1111/j.1476-5381.1983.tb11031.x}} 47. ^{{cite journal | vauthors = Caddy C, Giaroli G, White TP, Shergill SS, Tracy DK | title = Ketamine as the prototype glutamatergic antidepressant: pharmacodynamic actions, and a systematic review and meta-analysis of efficacy | journal = Therapeutic Advances in Psychopharmacology | volume = 4 | issue = 2 | pages = 75–99 | date = Apr 2014 | pmid = 24688759 | doi = 10.1177/2045125313507739 | pmc=3952483}} 48. ^{{cite journal | vauthors = Klockgether T, Turski L, Schwarz M, Sontag KH, Lehmann J | title = Paradoxical convulsant action of a novel non-competitive N-methyl-D-aspartate (NMDA) antagonist, tiletamine | journal = Brain Research | volume = 461 | issue = 2 | pages = 343–8 | date = Oct 1988 | pmid = 2846121 | doi = 10.1016/0006-8993(88)90265-X }} 49. ^{{cite journal | vauthors = Burns JM, Boyer EW | title = Antitussives and substance abuse | journal = Substance Abuse and Rehabilitation | volume = 4 | pages = 75–82 | year = 2013 | pmid = 24648790 | pmc = 3931656 | doi = 10.2147/SAR.S36761 }} 50. ^{{cite journal | vauthors = Aguayo LG, Warnick JE, Maayani S, Glick SD, Weinstein H, Albuquerque EX | title = Site of action of phencyclidine. IV. Interaction of phencyclidine and its analogues on ionic channels of the electrically excitable membrane and nicotinic receptor: implications for behavioral effects | journal = Molecular Pharmacology | volume = 21 | issue = 3 | pages = 637–47 | date = May 1982 | pmid = 6287200 }} 51. ^{{cite journal | vauthors = Zarantonello P, Bettini E, Paio A, Simoncelli C, Terreni S, Cardullo F | title = Novel analogues of ketamine and phencyclidine as NMDA receptor antagonists | journal = Bioorganic & Medicinal Chemistry Letters | volume = 21 | issue = 7 | pages = 2059–63 | date = Apr 2011 | pmid = 21334205 | doi = 10.1016/j.bmcl.2011.02.009 }} 52. ^{{cite journal | vauthors = Lin H, Vicini S, Hsu FC, Doshi S, Takano H, Coulter DA, Lynch DR | title = Axonal α7 nicotinic ACh receptors modulate presynaptic NMDA receptor expression and structural plasticity of glutamatergic presynaptic boutons | journal = Proceedings of the National Academy of Sciences of the United States of America | volume = 107 | issue = 38 | pages = 16661–6 | date = Sep 2010 | pmid = 20817852 | pmc = 2944730 | doi = 10.1073/pnas.1007397107 | bibcode = 2010PNAS..10716661L }} 53. ^{{cite journal | vauthors = Fisher JL, Dani JA | title = Nicotinic receptors on hippocampal cultures can increase synaptic glutamate currents while decreasing the NMDA-receptor component | journal = Neuropharmacology | volume = 39 | issue = 13 | pages = 2756–69 | date = Oct 2000 | pmid = 11044745 | doi = 10.1016/s0028-3908(00)00102-7 }} 54. ^{{cite journal | vauthors = Prestori F, Bonardi C, Mapelli L, Lombardo P, Goselink R, De Stefano ME, Gandolfi D, Mapelli J, Bertrand D, Schonewille M, De Zeeuw C, D'Angelo E | title = Gating of long-term potentiation by nicotinic acetylcholine receptors at the cerebellum input stage | journal = PLOS One | volume = 8 | issue = 5 | pages = e64828 | year = 2013 | pmid = 23741401 | pmc = 3669396 | doi = 10.1371/journal.pone.0064828 | bibcode = 2013PLoSO...864828P }} 55. ^{{cite journal | vauthors = Seeman P, Ko F, Tallerico T | title = Dopamine receptor contribution to the action of PCP, LSD and ketamine psychotomimetics | journal = Molecular Psychiatry | volume = 10 | issue = 9 | pages = 877–83 | date = Sep 2005 | pmid = 15852061 | doi = 10.1038/sj.mp.4001682 }} 56. ^{{cite journal | vauthors = Giannini AJ, Nageotte C, Loiselle RH, Malone DA, Price WA | title = Comparison of chlorpromazine, haloperidol and pimozide in the treatment of phencyclidine psychosis: DA-2 receptor specificity | journal = Journal of Toxicology. Clinical Toxicology | volume = 22 | issue = 6 | pages = 573–9 | year = 1984 | pmid = 6535849 | doi = 10.3109/15563658408992586 }} 57. ^{{cite journal | vauthors = Rothman RB, Reid AA, Monn JA, Jacobson AE, Rice KC | title = The psychotomimetic drug phencyclidine labels two high affinity binding sites in guinea pig brain: evidence for N-methyl-D-aspartate-coupled and dopamine reuptake carrier-associated phencyclidine binding sites | journal = Molecular Pharmacology | volume = 36 | issue = 6 | pages = 887–96 | date = Dec 1989 | pmid = 2557536 }} 58. ^{{cite journal | vauthors = Castellani S, Giannini AJ, Adams PM | title = Effects of naloxone, metenkephalin, and morphine on phencyclidine-induced behavior in the rat | journal = Psychopharmacology | volume = 78 | issue = 1 | pages = 76–80 | year = 1982 | pmid = 6815700 | doi = 10.1007/BF00470593 }} 59. ^1 {{cite web |title=Phencyclidine |url=https://www.drugbank.ca/drugs/DB03575 |website=www.drugbank.ca |accessdate=28 January 2019}} 60. ^1 2 {{cite journal |last1=Bey |first1=T |last2=Patel |first2=A |title=Phencyclidine intoxication and adverse effects: a clinical and pharmacological review of an illicit drug. |journal=The California Journal of Emergency Medicine |date=February 2007 |volume=8 |issue=1 |pages=9–14 |pmid=20440387 |pmc=2859735 }} 61. ^{{cite journal |last1=Johnson |first1=K M |last2=Jones |first2=S M |title=Neuropharmacology of Phencyclidine: Basic Mechanisms and Therapeutic Potential |journal=Annual Review of Pharmacology and Toxicology |date=April 1990 |volume=30 |issue=1 |pages=707–750 |doi=10.1146/annurev.pa.30.040190.003423 |pmid=2160793 }} 62. ^{{cite journal | vauthors = Olney JW, Labruyere J, Price MT | title = Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs | journal = Science | volume = 244 | issue = 4910 | pages = 1360–2 | date = Jun 1989 | pmid = 2660263 | doi = 10.1126/science.2660263 | bibcode = 1989Sci...244.1360O }} 63. ^{{cite book | vauthors = Hargreaves RJ, Hill RG, Iversen LL | title = Neuroprotective NMDA antagonists: the controversy over their potential for adverse effects on cortical neuronal morphology | journal = Acta Neurochirurgica. Supplementum | volume = 60 | issue = | pages = 15–9 | year = 1994 | pmid = 7976530 | doi = 10.1007/978-3-7091-9334-1_4 | isbn = 978-3-7091-9336-5 }} 64. ^Jansen, Karl. Ketamine: Dreams and Realities. MAPS, 2004. {{ISBN|0-9660019-7-4}} 65. ^{{cite journal | vauthors = Reynolds LM, Cochran SM, Morris BJ, Pratt JA, Reynolds GP | title = Chronic phencyclidine administration induces schizophrenia-like changes in N-acetylaspartate and N-acetylaspartylglutamate in rat brain | journal = Schizophrenia Research | volume = 73 | issue = 2–3 | pages = 147–52 | date = Mar 2005 | pmid = 15653257 | doi = 10.1016/j.schres.2004.02.003 }} 66. ^{{cite journal | vauthors = Murray JB | title = Phencyclidine (PCP): a dangerous drug, but useful in schizophrenia research | journal = The Journal of Psychology | volume = 136 | issue = 3 | pages = 319–27 | date = May 2002 | pmid = 12206280 | doi = 10.1080/00223980209604159 }} 67. ^{{cite journal|last1=Lodge|first1=D|last2=Mercier|first2=M S|title=Ketamine and phencyclidine: the good, the bad and the unexpected|journal=British Journal of Pharmacology|date=19 January 2017|volume=172|issue=17|pages=4254–4276|doi=10.1111/bph.13222|pmc=4556466|issn=0007-1188|pmid=26075331}} 68. ^{{cite journal|last1=Javitt|first1=Daniel C.|last2=Zukin|first2=Stephen R.|last3=Heresco-Levy|first3=Uriel|last4=Umbricht|first4=Daniel|title=Has an Angel Shown the Way? Etiological and Therapeutic Implications of the PCP/NMDA Model of Schizophrenia|journal=Schizophrenia Bulletin|date=19 January 2017|volume=38|issue=5|pages=958–966|doi=10.1093/schbul/sbs069|pmc=3446214|issn=0586-7614|pmid=22987851}} 69. ^{{cite web|url=http://www.erowid.org/archive/rhodium/chemistry/pcp/pcp_index.html|title=PCP synthesis and effects: table of contents|website=www.erowid.org}} 70. ^{{cite journal | vauthors = Itzhak Y, Kalir A, Weissman BA, Cohen S | title = New analgesic drugs derived from phencyclidine | journal = Journal of Medicinal Chemistry | volume = 24 | issue = 5 | pages = 496–9 | date = May 1981 | pmid = 7241506 | doi = 10.1021/jm00137a004 }} 71. ^{{cite journal | vauthors = Chaudieu I, Vignon J, Chicheportiche M, Kamenka JM, Trouiller G, Chicheportiche R | title = Role of the aromatic group in the inhibition of phencyclidine binding and dopamine uptake by PCP analogs | journal = Pharmacology Biochemistry and Behavior | volume = 32 | issue = 3 | pages = 699–705 | date = Mar 1989 | pmid = 2544905 | doi = 10.1016/0091-3057(89)90020-8 }} 72. ^1 2 3 {{cite book |last = Inciardi |first = James A. |title = The War on Drugs II|publisher = Mayfield Publishing Company |year = 1992 |isbn = 978-1-55934-016-8}} 73. ^Development of PCP, 2006, CESAR (Center for Substance Abuse Research) 74. ^{{cite book |year=2005 |author=Zukin, Stephen R |author2=Sloboda, Zili |author3=Javitt, Daniel C |chapter=Phencyclidine (PCP) |chapterurl=https://books.google.com/books?id=HtGb2wNsgn4C&pg=PA324&dq=Phencyclidine+history&hl=en&ei=lVH3TLLzJYrWvQOW-PCdDg&sa=X&oi=book_result&ct=result&resnum=7&ved=0CEIQ6AEwBg#v=onepage&q=Phencyclidine%20history&f=false|editor=Lowinson, Joyce H |editor2=Ruiz, Pedro |editor3=Millman, Robert B |editor3-link=Robert Millman |display-editors = 3 |editor4=Langrod, John G |title=Substance Abuse: A Comprehensive Textbook |edition=4th |place=Philadelphia |publisher=Lippincott Williams & Wilkins|isbn=978-0-7817-3474-5 |url=https://books.google.com/books?id=HtGb2wNsgn4C&printsec=frontcover&dq=substance+comprehensive+textbook#v=onepage&q&f=false |accessdate=2 December 2010}} 75. ^{{cite book |title=Drug Use and Abuse |last=Maisto |first=Stephen A. |author2=Mark Galizio |author3=Gerard Joseph Connors |year=2004 |publisher=Thompson Wadsworth |isbn=978-0-15-508517-6 }} 76. ^US Drug Enforcement Administration March 12, 2014 Controlled Substances Page accessed June 15, 2014 77. ^US Drug Enforcement Administration August 30, 2013. Established Aggregate Production Quotas for Schedule I and II Controlled Substances and Established Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2014 Page Accessed June 15, 2014 78. ^{{Cite web|title = The Misuse of Drugs Act 1971 (Modification) Order 1979|url = http://www.legislation.gov.uk/uksi/1979/299/article/2/made#text%253DPhencyclidine|website = www.legislation.gov.uk|access-date = 2016-01-31}} External links{{Commons category|Phencyclidine}}
| title = Recreational uses | titlestyle = background:#ccccff | list1 ={{Drug use}}{{Hallucinogens}}{{Euphoriants}}{{Stimulants}} }}{{Navboxes | title = Pharmacodynamics | titlestyle = background:#ccccff | list1 ={{Dopamine receptor modulators}}{{Ionotropic glutamate receptor modulators}}{{Monoamine reuptake inhibitors}}{{Nicotinic acetylcholine receptor modulators}}{{Opioid receptor modulators}}{{Sigma receptor modulators}} }} 14 : D2-receptor agonists|Dissociative drugs|Euphoriants|General anesthetics|German inventions|Monoamine reuptake inhibitors|Nicotinic antagonists|NMDA receptor antagonists|Opioids|Piperidines|Sigma agonists|Stimulants|RTT|Medical mnemonics |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 随便看 |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。